

NOVO NORDISK A S  
Form 6-K  
October 01, 2015

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

---

**FORM 6-K**

---

**REPORT OF FOREIGN PRIVATE ISSUER**

Pursuant to Rule 13a-16 or 15d-16  
of the Securities Exchange Act of 1934

**October 1, 2015**

---

**NOVO NORDISK A/S**

(Exact name of Registrant as specified in its charter)

**Novo Allé**

**DK- 2880, Bagsvaerd**

**Denmark**

Edgar Filing: NOVO NORDISK A S - Form 6-K

(Address of principal executive offices)

---

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F

Form 20-F  Form 40-F

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes  No

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g-32(b):82-\_\_\_\_\_

1/2

**Status regarding Novo Nordisk's holding of its own shares (30 September 2015)**

**Bagsværd, Denmark, 1 October 2015** – In continuation of the company's announcements dated 30 January 2015 and 30 April 2015 concerning planned share repurchase programmes, and pursuant to Section 204.25 of the New York Stock Exchange Listed Company Manual, this is to report that Novo Nordisk A/S (NYSE: NVO) and its wholly-owned affiliates on 30 September 2015 owned 40,730,571 of its own B shares of DKK 0.20, corresponding to a total nominal value of DKK 8,146,114 or 1.6% of the total share capital.

In the third quarter of 2015 a total of 13,142,200 B shares were repurchased, and 21,320 B shares were disposed of to employees in connection with employee incentive programmes.

*Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat other serious chronic conditions: haemophilia, growth disorders and obesity. Headquartered in Denmark, Novo Nordisk employs approximately 39,700 people in 75 countries and markets its products in more than 180 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit [novonordisk.com](http://novonordisk.com), Facebook, Twitter, LinkedIn, YouTube*

**Further information**

*Media:*

Anne Margrethe Hauge      +45 3079 3450      [amhg@novonordisk.com](mailto:amhg@novonordisk.com)

*Investors:*

Peter Hugreffe Ankersen      +45 3075 9085      [phak@novonordisk.com](mailto:phak@novonordisk.com)

Daniel Bohsen	+45 3079 6376	dabo@novonordisk.com
Melanie Raouzeos	+45 3075 3479	mrz@novonordisk.com
Kasper Veje	+45 3079 8519	kpvj@novonordisk.com
Frank Daniel Mersebach (US)	+1 609 235 8567	fdni@novonordisk.com

		Telephone:	Internet:
<b>Novo Nordisk A/S</b>	Novo Allé	+45 4444 8888	www.novonordisk.com
Investor Relations	2880 Bagsværd	Telefax:	CVR no:
	Denmark	+45 4444 6626	24 25 67 90
		Company announcement No 61 / 2015	

---

## SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.

NOVO NORDISK A/S

Date: October 1, 2015

Lars Rebien Sørensen,

Chief Executive Officer

